Form 4: Caris Life Sciences CEO Sells Shares for Tax

Caris Life Sciences CEO David D. Halbert reported a disposition of 141,956 shares of common stock to cover tax liabilities at a price of $29.75 per share.

Summary

• David D. Halbert, Founder, Chairman, and Chief Executive Officer of Caris Life Sciences, Inc. (CAI), reported a transaction on August 11, 2025.
• The transaction involved the disposition of 141,956 shares of Caris Life Sciences common stock.
• The shares were disposed of at a price of $29.75 per share.
• This disposition was made to cover tax liabilities, indicated by transaction code 'F'.
• Following this transaction, Mr. Halbert directly owns 2,295,133 shares and indirectly owns 121,025,002 shares through various entities.
• Indirect holdings include shares held by Caris Halbert, L.P. (101,261,532 shares), ADAPT I Ltd. (8,528,805 shares), Carisome I, L.P. (8,414,427 shares), Caris Investment II Ltd (645,149 shares), and Caris Investment III Ltd (2,175,089 shares).
• Mr. Halbert, as managing member of Caris Investment Management, LLC and trustee of two family trusts, has voting and investment power over these indirect holdings but disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 reporting a disposition of shares for tax liability, which is a common occurrence for executives. It does not indicate significant positive or negative operational news, but rather a compliance event.

Positives

• David D. Halbert, a key insider (Founder, Chairman, CEO, and 10% owner), retains significant beneficial ownership of over 123 million shares, indicating continued alignment with shareholder interests.

Negatives

• Disposition of 141,956 shares by a key insider, reducing their direct beneficial ownership.

Risks

• Potential for market misinterpretation of insider share disposition, even if for tax purposes, as a lack of confidence.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• David D. Halbert controls entities (Caris Investment Management, LLC and two family trusts) that hold a significant portion of the company's common stock, totaling 121,025,002 shares indirectly.

Stakeholder Impact

• Shareholders: Minor reduction in direct insider ownership, but overall significant insider stake remains. The transaction is for tax purposes, which is a common and expected event.

Key Dates

Recommendation

The filing is a standard Form 4 reporting a tax-related disposition of shares by a key insider. This is a routine event and does not provide new information that would significantly alter the investment thesis for Caris Life Sciences. The insider retains a substantial beneficial ownership, indicating continued long-term interest. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Caris Life Sciences, CAI, insider transaction, Form 4, beneficial ownership, David D. Halbert, stock disposition, tax liability, CEO, Chairman, Founder